Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 8/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.47 |
| ▸ | PTPRA | P18433 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14220651 | 0.87 | ME3 (0.47) | USP2CYP2C19MAPK1KMT2AALDH1A1 | |
| SCHEMBL4601956 | 0.86 | LTA4H (0.53) | USP2CYP2C19MAPK1CYP3A4MEN1 | |
| SCHEMBL4600696 | 0.84 | MEN1 (0.50) | MEN1KMT2AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL4600221 | 0.84 | AKR1C3 (0.46) | USP2CYP2C19MAPK1CYP3A4MEN1 | |
| SCHEMBL4601473 | 0.82 | FFAR4 (0.56) | USP2CYP2C19MAPK1CYP3A4MEN1 | |
| SCHEMBL27578112 | 0.82 | ITGB3 (0.44) | USP2CYP2C19MAPK1CYP3A4ALDH1A1 | |
| SCHEMBL21083725 | 0.82 | CYP3A4 (0.58) | USP2CYP2C19MAPK1CYP3A4MEN1 | |
| SCHEMBL4601060 | 0.80 | FFAR4 (0.58) | USP2CYP2C19MAPK1CYP3A4MEN1 | |
| SCHEMBL27742224 | 0.80 | ITGB3 (0.47) | USP2CYP2C19MAPK1CYP3A4MEN1 | |
| SCHEMBL9432297 | 0.79 | USP2 (0.56) | USP2CYP2C19MAPK1CYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1968995-A1 | METHODS FOR THE SYNTHESIS OF ARGININE-CONTAINING PEPTIDES | F. Hoffmann-la Roche AG (CH) | 2008-09-17 | — | — | EP | claimed |
| US-20070179279-A1 | Methods for the synthesis of arginine-containing peptides | ROCHE COLORADO CORPORATION | 2007-08-02 | — | — | US | claimed |
| WO-2007077112-A1 | METHODS FOR THE SYNTHESIS OF ARGININE-CONTAINING PEPTIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-12 | — | — | WO | claimed |
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| EP-3478672-B1 | BIARYLMETHYL HETEROCYCLES | UNIV MONTREAL (CA) | 2024-04-10 | — | — | EP | disclosed |
| US-20230045357-A1 | BIARYLMETHYL HETEROCYCLES | Université de Montréal (CA) | 2023-02-09 | — | — | US | disclosed |
| US-20230045357-A1 | BIARYLMETHYL HETEROCYCLES | Université de Montréal (CA) | 2023-02-09 | — | — | US | disclosed |
| US-11407733-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-08-09 | — | — | US | disclosed |
| US-20190202808-A1 | BIARYLMETHYL HETEROCYCLES | BRISTOL-MYERS SQUIBB COMPANY | 2019-07-04 | — | — | US | disclosed |
| US-20030229200-A1 | Selective linear peptides with melanocor tin-4 receptor (MC4-R) agonist activity | CHEN LI (US) | 2003-12-11 | — | — | US | disclosed |
| CN-1451017-A | Selective cyclic peptides | HOFFMANN LA ROCHE (CH) | 2003-10-22 | — | — | CN | disclosed |
| US-6600015-B2 | Treatment or prevention of obesity. | HOFFMANN-LA ROCHE INC. | 2003-07-29 | — | — | US | disclosed |
| EP-1315750-A2 | CYCLIC PEPTIDES HAVING MELANOCORTIN-4 RECEPTOR AGONIST ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-04 | — | — | EP | disclosed |
| EP-1272516-A2 | SELECTIVE LINEAR PEPTIDES WITH MELANOCORTIN-4 RECEPTOR (MC4-R) AGONIST ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-08 | — | — | EP | disclosed |
| US-20020143141-A1 | Selective cyclic peptides with melanocortin-4 receptor (MC4-R) agonist activity | CHEN LI (US) | 2002-10-03 | — | — | US | disclosed |
| WO-2002018437-A2 | CYCLIC PEPTIDES HAVING MELANOCORTIN-4 RECEPTOR AGONIST ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-07 | — | — | WO | disclosed |
| US-20010056179-A1 | Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity | HOFFMANN-LA ROCHE INC. | 2001-12-27 | — | — | US | disclosed |
| WO-2001074844-A2 | SELECTIVE LINEAR PEPTIDES WITH MELANOCORTIN-4 RECEPTOR (MC4-R) AGONIST ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143141-A1 | Selective cyclic peptides with melanocortin-4 receptor (MC4-R) agonist activity | MC4R, MC3R, MC1R | USP2 3661/4885CYP2C19 1973/4885MAPK1 2422/4885 |
| US-11407733-B2 | Biarylmethyl heterocycles | ARRB1, ADRB2, ADRB1 | USP2 3350/4885CYP2C19 628/4885MAPK1 1282/4885 |
| US-20030229200-A1 | Selective linear peptides with melanocor tin-4 receptor (MC4-R) agonist activity | MC4R, MC1R, MC3R | USP2 4770/4885CYP2C19 2236/4885MAPK1 1092/4885 |
| US-20190202808-A1 | BIARYLMETHYL HETEROCYCLES | ARRB1, ADRB2, ADRB1 | USP2 3350/4885CYP2C19 628/4885MAPK1 1282/4885 |
| US-20070179279-A1 | Methods for the synthesis of arginine-containing peptides | ARGLU1, PNISR, PRMT3 | USP2 1701/4885CYP2C19 4582/4885MAPK1 3692/4885 |
| US-12037324-B2 | Biarylmethyl heterocycles | ARRB1, ADRB2, ADRB1 | USP2 3350/4885CYP2C19 628/4885MAPK1 1282/4885 |
| US-20010056179-A1 | Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity | MC4R, MC3R, MC1R | USP2 4586/4885CYP2C19 2006/4885MAPK1 760/4885 |
| US-20230045357-A1 | BIARYLMETHYL HETEROCYCLES | ARRB1, ADRB2, ADRB1 | USP2 3350/4885CYP2C19 628/4885MAPK1 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.